Literature DB >> 24817340

An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome.

Sally Johnson1, Jelena Stojanovic, Gema Ariceta, Martin Bitzan, Nesrin Besbas, Michelle Frieling, Diana Karpman, Daniel Landau, Craig Langman, Christoph Licht, Carmine Pecoraro, Magdalena Riedl, Ekaterini Siomou, Nicole van de Kar, Johan Vande Walle, Chantal Loirat, C Mark Taylor.   

Abstract

BACKGROUND: In 2009, the European Paediatric Study Group for Haemolytic Uraemic Syndrome (HUS) published a clinical practice guideline for the investigation and initial therapy of diarrhea-negative HUS (now more widely referred to as atypical HUS, aHUS). The therapeutic component of the guideline (comprising early, high-volume plasmapheresis) was derived from anecdotal evidence and expert consensus, and the authors committed to auditing outcome.
METHODS: Questionnaires were distributed to pediatric nephrologists across Europe, North America, and the Middle East, who were asked to complete one questionnaire per patient episode of aHUS between July 1, 2009 and December 31, 2010. Comprehensive, anonymous demographic and clinical data were collected.
RESULTS: Seventy-one children were reported with an episode of aHUS during the audit period. Six cases occurred on a background of influenza A H1N1 infection. Of 71 patients, 59 (83 %) received plasma therapy within the first 33 days, of whom ten received plasma infusion only. Complications of central venous catheters occurred in 16 out of 51 patients with a catheter in-situ (31 %). Median time to enter hematological remission was 11.5 days, and eight of 71 (11 %) patients did not enter hematological remission by day 33. Twelve patients (17 %) remained dialysis dependent at day 33.
CONCLUSIONS: This audit provides a snapshot of the early outcome of a group of children with aHUS in the months prior to more widespread use of eculizumab.

Entities:  

Mesh:

Year:  2014        PMID: 24817340     DOI: 10.1007/s00467-014-2817-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  28 in total

Review 1.  Atypical hemolytic uremic syndrome.

Authors:  David Kavanagh; Timothy H J Goodship
Journal:  Curr Opin Hematol       Date:  2010-09       Impact factor: 3.284

2.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

Review 3.  A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders.

Authors:  N Besbas; D Karpman; D Landau; C Loirat; W Proesmans; G Remuzzi; G Rizzoni; C M Taylor; N Van de Kar; L B Zimmerhackl
Journal:  Kidney Int       Date:  2006-06-14       Impact factor: 10.612

Review 4.  Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes.

Authors:  Moglie Le Quintrec; Lubka Roumenina; Marina Noris; Véronique Frémeaux-Bacchi
Journal:  Semin Thromb Hemost       Date:  2010-09-23       Impact factor: 4.180

5.  Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants.

Authors:  Gema Ariceta; Beatriz Arrizabalaga; Mireia Aguirre; Elvira Morteruel; Margarita Lopez-Trascasa
Journal:  Am J Kidney Dis       Date:  2011-12-23       Impact factor: 8.860

6.  Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Lapeyraque; Véronique Frémeaux-Bacchi; Pierre Robitaille
Journal:  Pediatr Nephrol       Date:  2010-12-15       Impact factor: 3.714

7.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

8.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors:  C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

9.  Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome.

Authors:  Ramon Vilalta; Enrique Lara; Alvaro Madrid; Sara Chocron; Marina Muñoz; Alex Casquero; Jose Nieto
Journal:  Pediatr Nephrol       Date:  2012-08-14       Impact factor: 3.714

10.  Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome.

Authors:  Mathieu Lemaire; Véronique Frémeaux-Bacchi; Franz Schaefer; Murim Choi; Wai Ho Tang; Moglie Le Quintrec; Fadi Fakhouri; Sophie Taque; François Nobili; Frank Martinez; Weizhen Ji; John D Overton; Shrikant M Mane; Gudrun Nürnberg; Janine Altmüller; Holger Thiele; Denis Morin; Georges Deschenes; Véronique Baudouin; Brigitte Llanas; Laure Collard; Mohammed A Majid; Eva Simkova; Peter Nürnberg; Nathalie Rioux-Leclerc; Gilbert W Moeckel; Marie Claire Gubler; John Hwa; Chantal Loirat; Richard P Lifton
Journal:  Nat Genet       Date:  2013-03-31       Impact factor: 41.307

View more
  35 in total

1.  Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.

Authors:  Gema Ariceta
Journal:  Pediatr Nephrol       Date:  2019-01-28       Impact factor: 3.714

2.  Clinical guides for atypical hemolytic uremic syndrome in Japan.

Authors:  Hideki Kato; Masaomi Nangaku; Hiroshi Hataya; Toshihiro Sawai; Akira Ashida; Rika Fujimaru; Yoshihiko Hidaka; Shinya Kaname; Shoichi Maruyama; Takashi Yasuda; Yoko Yoshida; Shuichi Ito; Motoshi Hattori; Yoshitaka Miyakawa; Yoshihiro Fujimura; Hirokazu Okada; Shoji Kagami
Journal:  Clin Exp Nephrol       Date:  2016-08       Impact factor: 2.801

Review 3.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

4.  First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients.

Authors:  Selçuk Yüksel; Havva Evrengül; Z Birsin Özçakar; Tülay Becerir; Nagihan Yalçın; Emine Korkmaz; Fatih Ozaltin
Journal:  Paediatr Drugs       Date:  2016-12       Impact factor: 3.022

5.  Success of eculizumab in the treatment of atypical hemolytic uremic syndrome.

Authors:  Esra Baskin; Kaan Gulleroglu; Asli Kantar; Umut Bayrakci; Ozan Ozkaya
Journal:  Pediatr Nephrol       Date:  2014-11-11       Impact factor: 3.714

Review 6.  Advances and challenges in the management of complement-mediated thrombotic microangiopathies.

Authors:  Jean-Claude Davin; Nicole C A J van de Kar
Journal:  Ther Adv Hematol       Date:  2015-08

7.  Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.

Authors:  Naoko Ito; Hiroshi Hataya; Ken Saida; Yoshiro Amano; Yoshihiko Hidaka; Yaeko Motoyoshi; Toshiyuki Ohta; Yasuhiro Yoshida; Chikako Terano; Tadashi Iwasa; Wataru Kubota; Hidetoshi Takada; Toshiro Hara; Yoshihiro Fujimura; Shuichi Ito
Journal:  Clin Exp Nephrol       Date:  2015-07-09       Impact factor: 2.801

Review 8.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

9.  Atypical hemolytic uremic syndrome: a clinical conundrum.

Authors:  Prabesh Bajracharya; Amrish Jain; Rossana Baracco; Tej K Mattoo; Gaurav Kapur
Journal:  Pediatr Nephrol       Date:  2016-05-02       Impact factor: 3.714

10.  Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome.

Authors:  Priyanka Khandelwal; Aarti Gupta; Aditi Sinha; Savita Saini; Pankaj Hari; Marie-Agnes Dragon Durey; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2014-09-13       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.